Browsing ICR Divisions by author "Hafeez, Shaista"
Now showing items 21-34 of 34
-
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
Panebianco, V; Narumi, Y; Altun, E; Bochner, BH; Efstathiou, JA; et al. (ELSEVIER SCIENCE BV, 2018-09-01)CONTEXT: Management of bladder cancer (BC) is primarily driven by stage, grade, and biological potential. Knowledge of each is derived using clinical, histopathological, and radiological investigations. This multimodal ... -
Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry.
de Mol van Otterloo, SR; Christodouleas, JP; Blezer, ELA; Akhiat, H; Brown, K; et al. (ELSEVIER SCIENCE INC, 2021-11-15)PURPOSE: High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel ... -
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Hafeez, S; Warren-Oseni, K; McNair, HA; Hansen, VN; Jones, K; et al. (ELSEVIER SCIENCE INC, 2016-04-01)PURPOSE: Image guided adaptive radiation therapy offers individualized solutions to improve target coverage and reduce normal tissue irradiation, allowing the opportunity to increase the radiation tumor dose and spare ... -
Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance.
Hafeez, S; Patel, E; Webster, A; Warren-Oseni, K; Hansen, V; et al. (BMJ PUBLISHING GROUP, 2020-05-26)INTRODUCTION: Patients with muscle invasive bladder cancer (MIBC) who are unfit and unsuitable for standard radical treatment with cystectomy or daily radiotherapy present a large unmet clinical need. Untreated, they suffer ... -
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance.
Hafeez, S; Webster, A; Hansen, VN; McNair, HA; Warren-Oseni, K; et al. (BMJ PUBLISHING GROUP, 2020-12-31)INTRODUCTION: Daily radiotherapy delivered with radiosensitisation offers patients with muscle invasive bladder cancer (MIBC) comparable outcomes to cystectomy with functional organ preservation. Most recurrences following ... -
Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module.
Patel, E; Tsang, Y; Baker, A; Callender, J; Hafeez, S; et al. (ELSEVIER IRELAND LTD, 2019-11-01)BACKGROUND AND PURPOSE: Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating "Plan of the Day" (PoD) adaptive radiotherapy for bladder cancer. ... -
Quantitative analysis of diffusion weighted imaging in rectal cancer during radiotherapy using a magnetic resonance imaging integrated linear accelerator.
Ingle, M; Blackledge, M; White, I; Wetscherek, A; Lalondrelle, S; et al. (ELSEVIER, 2022-07-01)BACKGROUND AND PURPOSE: Magnetic resonance imaging integrated linear accelerator (MR-Linac) platforms enable acquisition of diffusion weighted imaging (DWI) during treatment providing potential information about treatment ... -
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Parker, C; Tunariu, N; Tovey, H; Alonzi, R; Blackledge, MD; et al. (OXFORD UNIV PRESS, 2023-10-31)BACKGROUND: Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation ... -
Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy.
Webster, A; McNair, HA; Hansen, VN; Lewis, R; Patel, E; et al. (Elsevier BV, 2022-03-01)Two multicentre adaptive radiotherapy trials utilising Plan of the Day (PoD) with a library of plans were introduced in 35 centres. The common issues that arose from all centres when introducing PoD were collated ... -
The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance.
Webster, A; Hafeez, S; Lewis, R; Griffins, C; Warren-Oseni, K; et al. (ELSEVIER SCIENCE LONDON, 2021-03-22)AIMS: Adaptive radiotherapy (ART) is an emerging advanced treatment option for bladder cancer patients. Therapeutic radiographers (RTTs) are central to the successful delivery of this treatment. The purpose of this work ... -
The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study.
Tan, MP; Harris, V; Warren-Oseni, K; McDonald, F; McNair, H; et al. (ELSEVIER SCIENCE LONDON, 2020-02-01)AIMS: Node-positive bladder cancer (NPBC) carries a poor prognosis and has traditionally been treated palliatively. However, surgical series suggest that a subset of NPBC patients can achieve long-term control after ... -
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.
de Mol van Otterloo, SR; Christodouleas, JP; Blezer, ELA; Akhiat, H; Brown, K; et al. (FRONTIERS MEDIA SA, 2020-09-07)Purpose: MR-guided Radiation Therapy (MRgRT) allows for high-precision radiotherapy under real-time MR visualization. This enables margin reduction and subsequent dose escalation which may lead to higher tumor control and ... -
Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.
Chau, C; Rimmer Frcr, Y; Choudhury PhD, A; Leaning Frcr, D; Law, A; et al. (ELSEVIER SCIENCE INC, 2021-07-15)PURPOSE: Small cell carcinoma of the bladder (SCCB) is rare, accounting for less than 1% of all bladder carcinomas. It is aggressive, and outcomes are poor as a result of its early metastatic spread. Owing to its rarity, ... -
Understanding the Benefit of Magnetic Resonance-guided Adaptive Radiotherapy in Rectal Cancer Patients: a Single-centre Study.
Ingle, M; White, I; Chick, J; Stankiewicz, H; Mitchell, A; et al. (ELSEVIER SCIENCE LONDON, 2022-11-03)AIMS: Neoadjuvant chemoradiotherapy followed by surgery is the mainstay of treatment for patients with rectal cancer. Standard clinical target volume (CTV) to planning target volume (PTV) margins of 10 mm are used to ...